Serenoa repens/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Increases maximum urinary flow rate (Qmax, peak flow)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Compared with placebo, the HESr was associated with 0.64 (95% confidence interval [CI] -0.98 to -0.31) fewer voids/night (P < 0.001) and an additional mean increase in Qmax of 2.75 mL/s (95% CI 0.57 to 4.93; P = 0.01).”
Quoted verbatim from Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.. - Study
- meta-analysis
- Dose
- 320 mg daily
- Population
- Men with LUTS/BPH; hexanic extract of Serenoa repens (HESr, Permixon) 320 mg daily vs placebo, pooled across RCTs and observational studies.
Effect 2.75 mean difference, 95% CI 0.57 to 4.93
Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.2019PMID:29694707Permalink
Keep reading
- Everything the graph holds on Serenoa repens
- Every compound studied against Maximum urinary flow rate (Qmax, peak flow)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M1G0QDZJMRX92DV50PJQP0T7